Boundless Bio, Inc.

NASDAQ:BOLD

Biotechnology

Healthcare
$2.38 +85.71%

+$1.20 today

Market cap
$56.20M
Beta
0.97
P/E (TTM)
-1.0
EPS (TTM)
-$2.50
52W Low $0.96High $2.75

Volume 0.13M

Average 0.22M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$46.66M

FY 2025 · Annual

Investing Cash Flow

$37.80M

FY 2025 · Annual

Financing Cash Flow

$141,000.00

FY 2025 · Annual

-99.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(25.21M)(45.9M)(49.43M)(65.36M)(58.2M)
Depreciation & Amortization682K942K957K1.09M1.25M
Deferred Income Tax00000
Stock-Based Compensation1.16M2.29M3.34M7.52M6.13M
Change in Working Capital(837K)866K(799K)(1.68M)3.46M
Accounts Receivables00000
Inventory00000
Accounts Payables01.91M0775K1.63M
Other Working Capital(837K)(1.05M)(799K)(2.45M)1.83M
Other Non-Cash Items959K2.21M(915K)(2.4M)698K
Operating Cash Flow(23.25M)(39.6M)(46.86M)(60.84M)(46.66M)
Capital Expenditures(2.03M)(1.07M)(633K)(2.54M)(546K)
Acquisitions (Net)00000
Purchases of Investments(77.49M)(42.6M)(160.12M)(208.47M)(174.9M)
Sales of Investments20.24M59.8M122.5M184.9M213.24M
Other Investing Activities00000
Investing Cash Flow(59.29M)16.13M(38.26M)(26.1M)37.8M
Debt Repayment00000
Common Stock Issued0126K093M141K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities208K0(1.77M)(3.18M)0
Financing Cash Flow105.53M126K97.9M89.82M141K
Effect of Forex Changes00000
Net Change in Cash22.99M(23.34M)12.78M2.88M(8.72M)
Free Cash Flow(25.28M)(40.66M)(47.49M)(63.38M)(47.21M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$58.2M
+ D&A$1.3M
+ Stock-Based Comp$6.1M
+ Deferred Tax$0
+ Working Capital$3.5M
+ Other Non-Cash$698.0K
= Operating Cash Flow-$46.7M
- Capex-$546.0K
= Free Cash Flow-$47.2M

Analysis

FY2025 free cash flow is -$47.2M. FCF conversion is 81.1% of net income. Operating cash flow was -$46.7M, with capex of -$546.0K. The largest bridge item is Stock-Based Comp at $6.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 10, 2026
4Statement of changes in beneficial ownershipNov 10, 2026
4Statement of changes in beneficial ownershipNov 5, 2026
EFFECTEFFECT filingNov 3, 2026
424B3424B3 filingNov 3, 2026

Does BOLD generate free cash flow?

Boundless Bio, Inc. (BOLD) generated -$47.21M of free cash flow in fiscal 2025.

How much operating cash flow does BOLD produce?

Operating cash flow was -$46.66M, before capital expenditures of $546,000.00.